Is The Santa Claus Rally The Gift That Keeps Giving?
Remember the horror of 2008 when the Great Recession hit…
Sell
20
ADAP Quote, Financials, Valuation and Earnings
Last price:
$0.58
Seasonality move
:
36.97%
Day range:
$0.58 - $0.59
52-week range:
$0.50 - $2.05
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
0.81x
P/B ratio:
1.85x
Volume:
1.2M
Avg. volume:
2.7M
1-year change:
15.76%
Market cap:
$148.1M
Revenue:
$60.3M
EPS (TTM):
-$0.18
Analysts' Opinion
-
Consensus RatingAdaptimmune Therapeutics PLC has received a consensus rating of Buy. The company's average rating is a Buy based on 4 Buy ratings, 2 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $3.50, Adaptimmune Therapeutics PLC has an estimated upside of 291.62% from its current price of $0.58.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $1.00 representing 100% downside risk from its current price of $0.58.
Fair Value
-
According to the consensus of 6 analysts, Adaptimmune Therapeutics PLC has 291.62% upside to fair value with a price target of $3.50 per share.
ADAP vs. S&P 500
-
Over the past 5 trading days, Adaptimmune Therapeutics PLC has underperformed the S&P 500 by -6.2% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
Adaptimmune Therapeutics PLC does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Adaptimmune Therapeutics PLC has grown year-over-year revenues for 2 quarters straight. In the most recent quarter Adaptimmune Therapeutics PLC reported revenues of $40.9M.
Earnings Growth
-
Adaptimmune Therapeutics PLC has grown year-over-year earnings for 0 quarters straight. In the most recent quarter Adaptimmune Therapeutics PLC reported earnings per share of -$0.06.
Enterprise value:
11.9M
EV / Invested capital:
0.09x
Price / LTM sales:
0.81x
EV / EBIT:
--
EV / Revenue:
0.07x
PEG ratio (5yr expected):
--
EV / Free cash flow:
-0.21x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
--
Return On Assets:
-15.08%
Net Income Margin (TTM):
-25.43%
Return On Equity:
-67.8%
Return On Invested Capital:
-55.22%
Operating Margin:
-35.89%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2023-09-30 | 2024-09-30 | |
| Income Statement | ||||||
| Revenue | $17.5M | $71.1M | $175M | $7.3M | $40.9M | |
| Gross Profit | -- | -- | -- | -- | -- | |
| Operating Income | -$179.6M | -$113.1M | -$45.1M | -$46.6M | -$14.7M | |
| EBITDA | -$172.7M | -$78.8M | -$57.2M | -$42M | -$12.9M | |
| Diluted EPS | -$1.08 | -$0.47 | -$0.18 | -$0.18 | -$0.06 | |
| Period Ending | 2020-09-30 | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $426.7M | $300.5M | $264.1M | $219.4M | $244.2M | |
| Total Assets | $479M | $353.5M | $332.2M | $296.6M | $317.4M | |
| Current Liabilities | $34.9M | $41.1M | $66.1M | $75.1M | $63.5M | |
| Total Liabilities | $102.8M | $112.5M | $218.9M | $208.5M | $237.4M | |
| Total Equity | $376.2M | $241M | $113.3M | $88.1M | $80M | |
| Total Debt | -- | -- | -- | -- | $49.9M | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2023-09-30 | 2024-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$9.9M | -$124.2M | -$53.7M | -$45.2M | -$54.5M | |
| Cash From Investing | $39.7M | $129.3M | $1.1M | $57.3M | -$66M | |
| Cash From Financing | $11.5M | $2.2M | $78.8M | $596K | $25M | |
| Free Cash Flow | -$40.2M | -$131.6M | -$56.1M | -$45.4M | -$54.9M | |
ADAP
Sector
Market Cap
$148.1M
$46.1M
Price % of 52-Week High
28.23%
46.02%
Dividend Yield
0%
0%
Shareholder Yield
-16.1%
-0.6%
1-Year Price Total Return
15.76%
-30.52%
Beta (5-Year)
2.179
0.772
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Technicals
8-day SMA
Sell
Level
$0.59
200-day SMA
Sell
Level
$1.03
Bollinger Bands (100)
Sell
Level
0.68 - 1.08
Chaikin Money Flow
Sell
Level
-105M
20-day SMA
Sell
Level
$0.64
Relative Strength Index (RSI14)
Sell
Level
34.54
ADX Line
Sell
Level
25.65
Williams %R
Buy
Level
-84.9375
50-day SMA
Sell
Level
$0.71
MACD (12, 26)
Sell
Level
-0.04
25-day Aroon Oscillator
Sell
Level
-36
On Balance Volume
Neutral
Level
150.5M
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (-5.4502)
Sell
CA Score
(Annual)
Level (-3.8078)
--
Beneish M-Score
(Annual)
Level (--)
Buy
Momentum Score
Level (7)
Sell
Ohlson Score
Level (4.5957)
--
Piotroski F Score
(Annual)
Level (--)
--
Quality Ratio Score
Level (--)
Buy
Fundamental Score
Level (5)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Adaptimmune Therapeutics PLC is a clinical-stage biopharmaceutical company. It focused on providing novel cell therapies to patients, particularly in solid tumors. It has developed a comprehensive proprietary platform that enables it to identify cancer targets, find and genetically engineer T-cell receptors, and produce TCR therapeutic candidates for administration to patients. Its programs include MAGE-A4 SPEAR T-cell therapy, NY-ESO SPEAR T-cell, CD70 and others for multiple cancer types.
Stock Forecast FAQ
In the current month, ADAP has received 4 Buy ratings 2 Hold ratings, and 0 Sell ratings. The ADAP average analyst price target in the past 3 months is $3.50.
-
Where Will Adaptimmune Therapeutics PLC Stock Be In 1 Year?
According to analysts, the consensus estimate is that Adaptimmune Therapeutics PLC share price will rise to $3.50 per share over the next 12 months.
-
What Do Analysts Say About Adaptimmune Therapeutics PLC?
Analysts are divided on their view about Adaptimmune Therapeutics PLC share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Adaptimmune Therapeutics PLC is a Sell and believe this share price will drop from its current level to $1.00.
-
What Is Adaptimmune Therapeutics PLC's Price Target?
The price target for Adaptimmune Therapeutics PLC over the next 1-year time period is forecast to be $3.50 according to 6 Wall Street analysts, 4 of them rate the stock a Buy, 0 rate the stock a Sell, and 2 analysts rate the stock a Hold.
-
Is ADAP A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Adaptimmune Therapeutics PLC is a Buy. 4 of 6 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of ADAP?
You can purchase shares of Adaptimmune Therapeutics PLC via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, TastyTrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Adaptimmune Therapeutics PLC shares.
-
What Is The Adaptimmune Therapeutics PLC Share Price Today?
Adaptimmune Therapeutics PLC was last trading at $0.58 per share. This represents the most recent stock quote for Adaptimmune Therapeutics PLC. Yesterday, Adaptimmune Therapeutics PLC closed at $0.58 per share.
-
How To Buy Adaptimmune Therapeutics PLC Stock Online?
In order to purchase Adaptimmune Therapeutics PLC stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is Alphabet an Undervalued Growth Stock to Buy?
Alphabet (NASDAQ:GOOGL) is easily one of the most successful companies…
Is Tesla Going to Buy Uber?
Tesla has always been in the habit of making large,…
Stock Ideas
Buy
65
Is AAPL Stock a Buy?
Market Cap: $3.9T
P/E Ratio: 42x
Buy
57
Is NVDA Stock a Buy?
Market Cap: $3.4T
P/E Ratio: 118x
Buy
58
Is MSFT Stock a Buy?
Market Cap: $3.3T
P/E Ratio: 37x
Alerts
Buy
87
PSIX alert for Dec 25
Power Solutions International [PSIX] is up 27.42% over the past day.
Buy
65
TSLL alert for Dec 25
Direxion Daily TSLA Bull 2X Shares [TSLL] is up 19.46% over the past day.
Buy
75
SMLR alert for Dec 25
Semler Scientific [SMLR] is up 15.37% over the past day.
